# Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

> **NCT00337389** · PHASE3 · UNKNOWN · sponsor: **Mast Therapeutics, Inc.** · enrollment: 1200 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** 5- Fluorouracil (5-FU)
- **DRUG:** bevacizumab (Avastin)
- **DRUG:** Leucovorin
- **DRUG:** CoFactor (ANX-510)

## Key facts

- **NCT ID:** NCT00337389
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2007-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337389, "Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00337389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*